Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)

被引：0

作者：

Larkin, J. ^{[1
]}

Chiarion-Sileni, V. ^{[2
]}

Gonzalez, R. ^{[3
]}

Grob, J. -J. ^{[4
]}

Cowey, C. L. ^{[5
]}

Lao, C. D. ^{[6
]}

Wagstaff, J. ^{[7
]}

Hogg, D. ^{[8
]}

Hill, A. ^{[9
]}

Carlino, M. S. ^{[10
,11
]}

Wolter, P. ^{[12
]}

Lebbe, C. ^{[13
]}

Schachter, J. ^{[14
]}

Thomas, L. ^{[15
]}

Hassel, J. C. ^{[16
]}

Lorigan, P. ^{[17
]}

Walker, D. ^{[18
]}

Jiang, J. ^{[19
]}

Hodi, F. S. ^{[20
]}

Wolchok, J. D. ^{[21
,22
]}

机构：

[1] Royal Marsden Hosp, London, England

[2] IOV IRCCS, Melanoma Oncol Unit, Padua, Italy

[3] Univ Colorado, Ctr Canc, Denver, CO 80202 USA

[4] Aix Marseille Univ, Hop La Timone AP, Marseille, France

[5] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[6] Univ Michigan, Ann Arbor, MI 48109 USA

[7] Singleton Hosp, South West Wales Canc Inst, Swansea SA2 8QA, W Glam, Wales

[8] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

[9] Tasman Oncol Res, Southport Gold Coast, Qld, Australia

[10] Melanoma Inst Australia, Sydney, NSW, Australia

[11] Univ Sydney, Sydney, NSW 2006, Australia

[12] UZ Leuven, Leuven, Belgium

[13] Univ Paris Diderot, Hop St Louis, Paris, France

[14] Inst Oncol, Tel Hashomer, Israel

[15] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

[16] Univ Heidelberg Hosp, German Canc Res Ctr, Heidelberg, Germany

[17] Christie NHS Fdn Trust, Manchester, England

[18] Bristol Myers Squibb Co, Princeton, NJ USA

[19] Bristol Myers Squibb, Hopewell, NJ USA

[20] Dana Farber Canc Inst, Boston, MA 02115 USA

[21] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[22] Weill Cornell Med Coll, New York, NY USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

0354

引用

页码：40 / 40

页数：1